Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06564753
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-16
Brief Title:
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Placebo-Controlled 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 randomized double-blind placebo-controlled parallel arm study of NA-931 in adults who are obese BMI 30 kgm2 or who are overweight BMI 27 kgm2 with at least one weight-related co-morbid condition
Detailed Description:
This is a Phase 2 13-week randomized double-blind placebo-controlled parallel arm study that will evaluate the safety tolerability weight loss efficacy pharmacodynamic effects and pharmacokinetics of NA-931 in adults who are obese BMI 30 kgm2 or who are overweight BMI 27 kgm2 with at least one weight-related co-morbid condition
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None